Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events-Reference-Cited by-同舟云学术

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events

Published:2021-11-02 Issue:24 Volume:127 Page:4546-4556
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ip Edward H.¹^ORCID,Saldana Santiago¹,Miller Kathy D.²,Carlos Ruth C.³^ORCID,Gareen Ilana F.⁴,Sparano Joseph A.⁵,Graham Noah⁶,Zhao Fengmin⁶⁷^ORCID,Lee Ju‐Whei⁶,O’Connell Nathaniel S.¹,Cella David⁸,Peipert John D.⁸^ORCID,Gray Robert J.⁶⁷,Wagner Lynne I.⁹^ORCID

Affiliation:

1. Department of Biostatistics and Data Science Wake Forest School of Medicine Winston‐Salem North Carolina

2. Hematology/Oncology Division Department of Medicine Indiana University School of Medicine Indianapolis Indiana

3. Department of Radiology University of Michigan Comprehensive Cancer Center Ann Arbor Michigan

4. Department of Epidemiology and Center for Statistical Sciences Brown University School of Public Health Providence Rhode Island

5. Department of Oncology Montefiore Medical Center Albert Einstein College of Medicine Bronx New York

6. ECOG‐ACRIN Biostatistics Center Dana‐Farber Cancer Institute Boston Massachusetts

7. Department of Biostatics Harvard T. H. Chan School of Public Health Boston Massachusetts

8. Department of Medical Social Sciences Feinberg School of Medicine Northwestern University Chicago Illinois

9. Department of Social Sciences and Health Policy Wake Forest School of Medicine Winston‐Salem North Carolina

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33992

Reference26 articles.

1. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)

2. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

3. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

4. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

5. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to S. Zhang et al and S. Selukar;Journal of Clinical Oncology;2024-07-01

2. Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial;Journal of Clinical Oncology;2024-01-20

3. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF;European Journal of Pharmacology;2023-06